Leadership

David Cory is a biopharmaceutical industry leader with 30 years of operational experience in public and private, large pharma and emerging stage biotechnology companies, with an extensive commercial background spanning multiple launches including global blockbuster products and targeted therapeutics for rare diseases, an established track record in the capital markets with over $1B+ raised and multiple companies which have successfully resulted in acquisition.
 
Mr. Cory was previously President and CEO, Director, and co-founder of Eiger BioPharmaceuticals, a commercial-stage biopharmaceutical company focused on the development of innovative therapies for serious, orphan diseases, and was responsible for negotiating multiple technology and product licenses from Stanford University, Merck, BMS, The Progeria Research Foundation, and Children’s Hospital of Philadelphia to build the pipeline, taking the company public, and obtaining the company’s first FDA and EMA product approvals. Previously, Mr. Cory was President and Chief Operating Officer of Prestwick Pharmaceuticals, an orphan CNS specialty pharmaceutical company, which was acquired by Biovail for $160 million. Earlier, Mr. Cory was a co-founder of CoTherix, an orphan pulmonary arterial hypertension company, which was acquired by Actelion for $425 million. Mr. Cory began his biotech career with the founding team at InterMune, focused on developing orphan products for idiopathic pulmonary fibrosis, where he was Senior Vice President and a key executive in the company IPO, in-licensing 4 products, and building and managing the company’s commercial organization. InterMune was acquired by Roche for $8 billion. Mr. Cory spent over a decade in large pharma in positions of increasing responsibilities in commercial operations at Glaxo, Glaxo Welcome, and Glaxo Smith Kline where he led teams in oncology, critical care, CNS, infectious disease, and respiratory therapeutic areas, and directed 10 newly approved pharmaceutical product launches. Mr. Cory began his pharmaceutical career at The Upjohn Company.
 
Mr. Cory earned a BS in Pharmacy from the University of Cincinnati, College of Pharmacy, was board certified in Pharmacy in the state of Ohio and holds an MBA from the University of Maryland.

Dr Stein received his medical degree and PhD, from the University of Witwatersrand Medical School in Johannesburg, South Africa. In 1972 he started the first Lipid Clinic in South Africa and described the very high gene frequency of FH in the Afrikaner population. After completing his specialist training in Medical Biochemistry at McMaster University Medical Center in Canada he spent 11 years as a full-time faculty member at the University of Cincinnati, Ohio, , achieving the rank of tenured Professor of Pathology and Laboratory Medicine and Associate Professor of Internal Medicine. In 1988, he moved his clinical and laboratory groups and formed the Metabolic and Atherosclerosis Research Center, specializing in clinical trials affecting lipid metabolism and Medical Research Laboratories (MRL) a global central lab for clinical trials. In 2002 MRL was acquired by Pharmaceutical Product Development Inc. In 2006 he rejoined Dr Troendle with whom he had founded Medpace and developed Medpace Reference Laboratories. He remained on the Medpace board until 2012.

Dr. Stein has had a number of appointments to the National Institutes of Health (NIH) since 1986, including the National Cholesterol Education Program. He served on the Data and Safety Advisory Board of the National Heart, Lung, and Blood Institute Program on Genetics in Hypertension from 1999-2003. In 2006 he was appointed to the FDA Clinical Chemistry and Clinical Toxicology Advisory Panel through 2010.

Over the last 35 years Dr. Stein has been an Advisory Board member for a number of pharmaceutical and biotech companies in the lipid area and a member of the board of directors of Xenon Pharmaceuticals, CymaBay and Medpace CRO.

Prior to joining LIB Therapeutics as Chief Medical Officer in 2020, Dr. Kallend was the CMO at The Medicines Company, overseeing the clinical development program for inclisiran, the siRNA for PCSK9, from inception through to NDA and MAA filings. From 2005 to 2012, he was the Global Clinical Leader and a Group Medical Director at Roche and was responsible for Phase 2 and Phase 3 clinical development of dalcetrapib and an advisor to other lipid programs in early- and late-stage development at Roche and Genentech. Prior to this, Dr. Kallend worked at AstraZeneca (UK) on the clinical development of rosuvastatin from Phase 2 to Phase 4 through post-approval. He was also involved in assessment of other therapies for the metabolism portfolio. Dr. Kallend began his career in the pharmaceutical industry as an International Clinical Research Physician working on imaging studies for Schering AG in Berlin, predominantly in the area of magnetic resonance imaging and contrast media diagnostics.

Dr. Kallend graduated from Kings College Hospital School of Medicine in London, and did his postgraduate training at the Royal Postgraduate Medical School, Hammersmith Hospital, London, finishing as a Research Fellow in the Department of Surgery.

Dr. Shekar Ganesa joined LIB Therapeutics in 2020 with 25+ years’ experience and manages the strategic/technical activities related to Process and Analytical development, Manufacturing, Quality, Supply chain, CMC regulatory initiatives at various CDMO’s and CRO’s for Lerodalcibep (LIB003).

Prior to LIB Therapeutics, Shekar has held several leadership roles at MassBiologics, Amgen and Genzyme-Sanofi leading cell line development/banking, upstream, downstream, formulation and analytical development activities for monoclonal antibodies, recombinant complex glycoproteins and gene therapy viral vector-based products leading to several successful INDs filings and BLAs approvals. Shekar continues to be a strong advocate of implementing Quality by Design (QbD) principles to understand, design and control critical product quality attributes while optimizing process performance.

Shekar has published numerous research articles and delivered keynote lectures at several national and international meetings. Dr. Shekar Ganesa received his Ph.D. in Biochemistry from Indiana State University, Terre Haute, IN and subsequently completed a post-doctoral fellowship in Biochemistry at the Worcester Foundation for Experimental Biology.

Dr Choong brings more than 20 years of experience in start-up and operating roles in both private and publicly traded biotechnology companies from preclinical stage through clinical development, product approval and commercialization. Most recently she served as Chief Business Officer at Eiger BioPharmaceuticals. As a member of the founding team at Eiger, she transitioned from the bench into executive level operational roles over the next decade including clinical and regulatory development across multiple programs and therapeutic areas, investor relations, financing, business development and corporate communications. These efforts included the US and EU approval and launch of Zokinvy (lonafarnib), the first and only treatment approved to extend survival in Hutchinson-Gilford Progeria Syndrome, a rare fatal genetic condition in children. Dr Choong started her industry career at Sunesis Pharmaceuticals as a Principal Scientist in Lead Discovery Research.

Dr Choong earned a BS in Chemistry from the California Institute of Technology and a PhD in Chemistry from the University of California at Berkeley.

Mr. Stephen P. Ewald, J.D. serves as General Counsel, Corporate Secretary of the Company. Stephen P. Ewald joined Medpace as General Counsel and Corporate Secretary in June 2012.

Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011, he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009, serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities.

Mr. Ewald has served as director for several private companies, including as a director of Symplmed Pharmaceuticals, LLC since 2013, as a director of LIB Therapeutics, LLC since 2016 and as a director of CinRx Pharma, LLC since 2016. Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.